

# Sonali Kochhar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2945769/publications.pdf>

Version: 2024-02-01

98  
papers

28,684  
citations

100601

38  
h-index

42259

96  
g-index

101  
all docs

101  
docs citations

101  
times ranked

47726  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccine strategies must focus on severe disease and global equity. <i>Lancet</i> , The, 2022, 399, 406-410.	6.3	55
2	Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. <i>Vaccine</i> , 2022, 40, 1681-1690.	1.7	9
3	WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations. <i>Vaccine</i> , 2022, 40, 2140-2149.	1.7	11
4	Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. <i>Vaccine</i> , 2021, 39, 85-120.	1.7	111
5	Expecting the unexpected with COVID-19 vaccines. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 150-151.	4.6	4
6	Suitability of databases in the <sc>Asia-Pacific</sc> for collaborative monitoring of vaccine safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 843-857.	0.9	5
7	Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group. <i>Nature Medicine</i> , 2021, 27, 569-570.	15.2	8
8	COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). <i>Vaccine</i> , 2021, 39, 2504-2505.	1.7	1
9	The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). <i>Vaccine</i> , 2021, 39, 3050-3052.	1.7	3
10	Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. <i>Lancet HIV</i> , the, 2021, 8, e363-e375.	2.1	32
11	Time for action: towards an intersectional gender approach to COVID-19 vaccine development and deployment that leaves no one behind. <i>BMJ Global Health</i> , 2021, 6, e006854.	2.0	16
12	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , the, 2021, 8, e633-e651.	2.1	56
13	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 37-59.	4.6	104
14	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 60-79.	4.6	95
15	Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234.	13.7	128
16	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. <i>Vaccine</i> , 2020, 38, 6184-6189.	1.7	6
17	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. <i>Vaccine</i> , 2020, 38, 5734-5739.	1.7	6
18	Planning for COVID-19 vaccines safety surveillance. <i>Vaccine</i> , 2020, 38, 6194-6198.	1.7	51

#	ARTICLE	IF	CITATIONS
19	Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. <i>Vaccine</i> , 2020, 38, 7702-7707.	1.7	6
20	Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. <i>Journal of Infectious Diseases</i> , 2020, 222, 180-182.	1.9	12
21	Obstetrics risk Assessment: Evaluation of selection criteria for vaccine research studies in pregnant women. <i>Vaccine</i> , 2020, 38, 4542-4547.	1.7	0
22	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. <i>Vaccine</i> , 2020, 38, 5556-5561.	1.7	9
23	Group B streptococcal disease in the mother and newbornâ€”A review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 526-533.	0.5	19
24	Ethics of Conducting Clinical Research in an Outbreak Setting. <i>Annual Review of Virology</i> , 2020, 7, 475-494.	3.0	10
25	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. <i>Vaccine</i> , 2020, 38, 7708-7715.	1.7	4
26	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€”2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , the, 2019, 6, e831-e859.	2.1	341
27	Introduction of new vaccines for immunization in pregnancy â€” Programmatic, regulatory, safety and ethical considerations. <i>Vaccine</i> , 2019, 37, 3267-3277.	1.7	33
28	Diseases, Injuries, and Risk Factors in Child and Adolescent Health, 1990 to 2017. <i>JAMA Pediatrics</i> , 2019, 173, e190337.	3.3	140
29	Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions. <i>Vaccine</i> , 2019, 37, 2967-2974.	1.7	13
30	Clinical trial data sharing: hereâ€™s the challenge. <i>BMJ Open</i> , 2019, 9, e032334.	0.8	20
31	Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2019, 37, 7610-7622.	1.7	30
32	Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2019, 37, 7596-7609.	1.7	37
33	Neurodevelopmental delay: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2019, 37, 7623-7641.	1.7	41
34	Postpartum endometritis and infection following incomplete or complete abortion: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2019, 37, 7585-7595.	1.7	22
35	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 69-89.	5.2	326
36	Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. <i>Vaccine</i> , 2019, 37, 5796-5802.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Assessing feasibility of resources at health facilities in Uganda to diagnose pregnancy and neonatal outcomes. <i>International Health</i> , 2019, 11, 128-135.	0.8	4
38	Postpartum endometritis: development of a maternal outcome definition for international immunization research through the GAIA project. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 654-655.	0.7	0
39	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
40	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
41	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
42	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
43	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
44	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
45	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
46	Chorioamnionitis: development of a maternal outcome definition for international immunization research through the GAIA project. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 654.	0.7	0
47	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1329-1349.	4.6	144
48	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S123-S139.	1.0	6
49	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1191-1210.	4.6	1,084
50	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1211-1228.	4.6	862
51	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
52	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
53	Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. <i>Vaccine</i> , 2017, 35, 6575-6581.	1.7	22
54	Safety assessment of immunization in pregnancy. <i>Vaccine</i> , 2017, 35, 6469-6471.	1.7	25

#	ARTICLE	IF	CITATIONS
55	Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. <i>Vaccine</i> , 2017, 35, 6472-6482.	1.7	46
56	Low birth weight: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2017, 35, 6492-6500.	1.7	226
57	Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. <i>Vaccine</i> , 2017, 35, 6518-6528.	1.7	94
58	Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2017, 35, 6546-6554.	1.7	24
59	Gestational diabetes mellitus: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2017, 35, 6555-6562.	1.7	6
60	Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2017, 35, 6563-6574.	1.7	36
61	Antenatal bleeding: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2017, 35, 6529-6537.	1.7	6
62	Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. <i>Vaccine</i> , 2017, 35, 6501-6505.	1.7	9
63	Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2017, 35, 6538-6545.	1.7	14
64	Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. <i>Vaccine</i> , 2017, 35, 6483-6491.	1.7	17
65	Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2017, 35, 6506-6517.	1.7	38
66	Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2016, 34, 6597-6609.	1.7	53
67	The importance of the patient voice in vaccination and vaccine safety—“are we listening?”. <i>Clinical Microbiology and Infection</i> , 2016, 22, S146-S153.	2.8	34
68	Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. <i>Vaccine</i> , 2016, 34, 6007-6014.	1.7	22
69	Global alignment of immunization safety assessment in pregnancy – The GAIA project. <i>Vaccine</i> , 2016, 34, 5993-5997.	1.7	72
70	Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6084-6092.	1.7	41
71	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. <i>Vaccine</i> , 2016, 34, 5998-6006.	1.7	42
72	Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2016, 34, 6057-6068.	1.7	122

#	ARTICLE	IF	CITATIONS
73	Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6015-6026.	1.7	74
74	Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. <i>Vaccine</i> , 2016, 34, 6038-6046.	1.7	44
75	Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6093-6101.	1.7	13
76	Maternal death: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6077-6083.	1.7	18
77	Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6102-6109.	1.7	20
78	Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6069-6076.	1.7	18
79	Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6027-6037.	1.7	63
80	Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. <i>Vaccine</i> , 2016, 34, 6047-6056.	1.7	282
81	Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. <i>Vaccine</i> , 2016, 34, 6617-6625.	1.7	21
82	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. <i>Vaccine</i> , 2016, 34, 6634-6640.	1.7	41
83	Communicating Vaccine Safety During the Development and Introduction of Vaccines. <i>Current Drug Safety</i> , 2015, 10, 55-59.	0.3	5
84	Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004118.	1.3	27
85	Global lessons from Nigeria's ebolavirus control strategy. <i>Expert Review of Vaccines</i> , 2015, 14, 1397-1400.	2.0	8
86	Standardization and simplification of vaccination records. <i>Expert Review of Vaccines</i> , 2014, 13, 545-559.	2.0	14
87	Template protocol for clinical trials investigating vaccines—Focus on safety elements. <i>Vaccine</i> , 2013, 31, 5602-5620.	1.7	17
88	Impact, Challenges, and Future Projections of Vaccine Trials in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 414-419.	0.6	24
89	Introducing new vaccines in developing countries. <i>Expert Review of Vaccines</i> , 2013, 12, 1465-1478.	2.0	43
90	Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers. <i>PLoS ONE</i> , 2013, 8, e55831.	1.1	41

#	ARTICLE	IF	CITATIONS
91	Promoting Evidence-based Vaccine Safety Research and Communication--The Vienna Vaccine Safety Initiative. <i>Journal of Tropical Pediatrics</i> , 2012, 58, 167-169.	0.7	3
92	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 630-638.	1.4	4
93	Prioritizing polio. <i>Expert Review of Vaccines</i> , 2012, 11, 1389-1392.	2.0	5
94	Safety reporting in developing country vaccine clinical trials--A systematic review. <i>Vaccine</i> , 2012, 30, 3255-3265.	1.7	19
95	Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. <i>Indian Journal of Medical Research</i> , 2010, 132, 168-75.	0.4	6
96	P14-01. Care and treatment for volunteers in IAVI-sponsored HIV vaccine clinical trials in India. <i>Retrovirology</i> , 2009, 6, .	0.9	0
97	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1107-1116.	0.5	53
98	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 873-880.	0.5	43